BioNTech veröffentlicht am 5. August 2024 Ergebnisse für das zweite Quartal 2024 und informiert über operativen Fortschritt MAINZ, Deutschland...
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024 MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union The updated COVID-19...
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2...
BioNTech und CEPI erweitern Partnerschaft zur Stärkung des afrikanischen mRNA-Impfstoff-Ökosystems BioNTech und die Coalition for...
BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten MAINZ, Deutschland, 21...
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech...
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update Advancing toward goal of ten or more potentially registrational...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.